-
Dr. Shen Huaqiong from Tianjing Biotech will leave his post. Exclusive reply: I hope to return to our business——CNS drug development
Time of Update: 2021-12-25
Huaqiong Shen before joining Tianjing Biotechnology, and talked about its career from accidental "medicine" to compound doctor, from clinical drug researcher to pharmacist .
Shen Huaqiong's resignation broke out, Tianjing Bio also reported a number of executive personnel changes:Dr.
-
The harvest time for new Chinese medicines has come, and the number of approved drugs hits a record high
Time of Update: 2021-12-25
In short, innovative research and development of traditional Chinese medicine is rapidly emerging .
-
Clinical trials are increasingly "burning money", how should innovative pharmaceutical companies deal with the challenges?
Time of Update: 2021-12-25
For example, Fuhong Henlius recently revealed on the Global R&D Day that a large internal clinical trial project, compared to handing over to a CRO (contract research organization) enterprise, a self-built clinical trial team can The patient's cost is reduced by nearly half .
-
BD announces major acquisitions to expand into new markets
Time of Update: 2021-12-25
The Venclose™ radiofrequency ablation system strategically complements our portfolio of leading venous disease technologies and remains in line with our focus Unanimous innovation provides transformative solutions to improve the treatment of chronic diseases and make it possible to transition to a new care environment .
-
Over 1 billion U.S. dollars!
Time of Update: 2021-12-25
The company is using its proprietary XPAT and XPAC platforms to develop a series of new drugs that can be preferentially activated in the tumor microenvironment to overcome the side effects of T cell therapy and cytokine therapy .
-
Notice on soliciting opinions on the standards of 8 pharmaceutical excipients to be included in the Chinese Pharmacopoeia, including triethanolamine
Time of Update: 2021-12-24
According to the "Chinese Pharmacopoeia" medicinal excipients selection principle (the medicinal excipients that have been used in domestic and foreign preparations and whose safety has been confirmed), the relevant pharmaceutical excipient manufacturers and users are invited to give feedback on the proposed new standards The following information: The company produces or uses the pharmaceutical excipients, when the pharmaceutical excipients have been applied to which domestically marketed preparations, and how safe are the excipients and preparations .
-
Today is different from the past, and local innovative pharmaceutical companies are speeding up overseas!
Time of Update: 2021-12-24
In addition to BeiGene, on August 8 this year, Rongchang Biotech announced that it has reached an exclusive global license agreement with Seattle Gene.
The industry predicts that in the context of the gradual trend of local innovative drugs going overseas, the number of license-out projects will increase in the future .
-
The results of large-scale collection of proprietary Chinese medicines are announced!
Time of Update: 2021-12-24
On the evening of December 21, the Hubei Provincial Inter-provincial Alliance of Chinese Patent Medicines Central Procurement Leading Group Office issued the "Announcement of the Proposed Selection R
-
A major overhaul is ushered in 14 years!
Time of Update: 2021-12-24
The background of the Chinese version of the new regulations on drug management and use At the beginning of 2019, the State Food and Drug Administration officially launched the revision of the "Measures for the Supervision and Administration of Drug Sales" and organized a special drafting team.
-
Pfizer's Acute Leukemia Drug Ogaituzumab for Injection Approved in China
Time of Update: 2021-12-24
On December 22, Pfizer announced that the National Medical Products Administration of China has approved Bebossa® (Ogaituzumab for injection) for relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R /R B-ALL) adult patients, this is also the world's first approved antibody-drug conjugate (ADC) for the treatment of R/R B-ALL .
-
The second!
Time of Update: 2021-12-24
Source: NextPharmaAt present, there are 3 indications approved in China for the research of tocilizan antigen, namely: adult rheumatoid arthritis, systemic juvenile idiopathic arthritis and cytokine release syndrome .
Among them, domestic companies that develop tocilizumab biosimilar drugs include Hisun Pharmaceuticals, Livzon Pharmaceuticals, and Biotech Biopharmaceuticals .
-
1961-2021 Colorcon celebrates its 60th anniversary and builds a better future together!
Time of Update: 2021-12-24
Glory moment-a piece of cake creates glory In 2021, Colorcon will celebrate its 60th anniversary and will witness this glorious moment with its global subsidiaries and customers . Since its es
-
FDA outlines the focus of generic drug research in fiscal year 2022, focusing on complex generic drugs and equivalent tool methods and nitrosamine testing
Time of Update: 2021-12-24
Based on feedback, the FDA has revised the scientific and research priority B1 for fiscal year 2022, including not only the improvement of the PBPK model, but also the CFD model CFD can support an alternative method of demonstrating the bioequivalence (BE) of oral inhalation products .
-
Notice on Public Solicitation of ICH Guiding Principles "M7(R2)"
Time of Update: 2021-12-24
See the attachment for the original text and Chinese translation of M7 (R2).
M7 (R2) appendix Chinese translation ICH work office December 21, 2021 Relevant attachments Serial number accessory name 1 English text of M7(R2).
docx 4 M7(R2) appendix Chinese translation.
-
In December, the wave of resignations of pharmaceutical company executives continued
Time of Update: 2021-12-24
It is worth noting that, in addition to the successive announcements of senior management changes by Tianjing Biotechnology, according to incomplete statistics, since December, many senior executives in the pharmaceutical industry have also resigned .
-
The results of the national talks are released. The full analysis of key products involves Hengrui, Rongchang, and Geli Pharmaceuticals, etc.
Time of Update: 2021-12-24
, Fluzoparil Capsules, Hetropopaethanolamine Tablets, and Azilsartan Tablets; Two new drugs are included in the 2021 medical insurance list by Golly Pharmaceuticals and Rongchang Biologics, namely danorevir sodium tablets and ravi hydrochloride Davir tablets, vedicitumumab for injection, and taltacept for injection .
-
Since December, public offerings have been intensively investigated, and these pharmaceutical and biological companies have been targeted
Time of Update: 2021-12-24
It is reported that in the field of medical biology, Haier Biotechnology, New Industries, and International Medicine have welcomed more than 40 fund companies to investigate .
-
There is huge demand in the ophthalmology medical field, and a large number of pharmaceutical companies are accelerating their deployment
Time of Update: 2021-12-24
In addition to increasing R&D investment and exploring breakthrough new ophthalmic drugs and therapies, cooperation between pharmaceutical companies in this field will also be normalized .
-
Notice on the solicitation of samples for research on the subject of raising the standard of pharmaceutical excipients (the second time in 2021)
Time of Update: 2021-12-24
Contact number: 010﹣67079620, 67079566 Appendix: List of samples for research on the improvement of pharmaceutical excipient standards (second batch in 2021).
-
AstraZeneca's new indications for major complement C5 inhibitors receive FDA priority review qualification
Time of Update: 2021-12-24
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn December 21, AstraZeneca announced that it had acquired a supplementary license application (sBLA) for the complement C5 inhibitor Ultomiris (ravulizumab-cwvz), a leading company on the complement track, for the treatment of adult systemic myasthenia gravis (gMG).
